Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 5/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7728957 | 0.94 | PLCG1 (0.37) | PLCG1ELANEHTR2AL3MBTL1HTT | |
| SCHEMBL7728647 | 0.94 | ELANE (0.36) | PLCG1ELANEHTR2AL3MBTL1HTT | |
| SCHEMBL7722446 | 0.94 | ELANE (0.36) | PLCG1ELANEHTR2AL3MBTL1HTT | |
| SCHEMBL7730458 | 0.94 | PLCG1 (0.35) | PLCG1ELANEHTR2AL3MBTL1HTT | |
| SCHEMBL7730230 | 0.94 | PLCG1 (0.35) | PLCG1ELANEHTR2AL3MBTL1HTT | |
| SCHEMBL7631759 | 0.93 | PLCG1 (0.36) | PLCG1ELANEHTR2AL3MBTL1HTT | |
| SCHEMBL7731024 | 0.93 | PLCG1 (0.35) | PLCG1ELANEHTR2AL3MBTL1HTT | |
| SCHEMBL7722351 | 0.92 | PLCG1 (0.34) | PLCG1ELANEHTR2AL3MBTL1HTT | |
| SCHEMBL7630879 | 0.92 | PLCG1 (0.34) | PLCG1ELANEHTR2AL3MBTL1HTT | |
| SCHEMBL7729474 | 0.92 | PLCG1 (0.34) | PLCG1ELANEHTR2AL3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030149016-A1 | Novel carbapenem derivatives | KANO YUKO (JP) | 2003-08-07 | — | — | US | disclosed |
| US-6458780-B1 | IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149016-A1 | Novel carbapenem derivatives | DPEP1, TMPRSS15, STK35 | PLCG1 1638/4885ELANE 1214/4885HTR2A 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.